Clinical value of ⁶⁸Ga-pentixafor PET/CT in patients with primary aldosteronism and bilateral lesions: preliminary results of a single-centre study.

IF 3.1 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

EJNMMI Research Pub Date : 2024-07-04 DOI:10.1186/s13550-024-01125-2

Rui Zuo, Shuang Liu, Wenbo Li, Zhu Xia, Lu Xu, Hua Pang

{"title":"Clinical value of 68Ga-pentixafor PET/CT in patients with primary aldosteronism and bilateral lesions: preliminary results of a single-centre study.","authors":"Rui Zuo, Shuang Liu, Wenbo Li, Zhu Xia, Lu Xu, Hua Pang","doi":"10.1186/s13550-024-01125-2","DOIUrl":null,"url":null,"abstract":"Background: Subtype diagnosis of primary aldosteronism (PA) is used to determine treatment, and the potential utility of 68Ga-pentixafor PET/CT for investigation of PA has long been recognized. The study aimed to evaluate the clinical value of 68Ga-pentixafor PET/CT in the diagnosis and prognosis of patients with bilateral lesions identified by CT.Methods: In total, 25 patients with PA and bilateral lesions on CT were retrospectively evaluated. All patients underwent 68Ga-Pentixafor PET/CT and adrenal vein sampling. The analysis focused on establishing the relationship between bilateral adrenal lesions SUVmax and the ratio of bilateral adrenal lesions SUVmax (CON) and clinical diagnosis, treatment outcomes, and KCNJ5 gene status.Results: The concordance rate between 68Ga-Pentixafor PET/CT and adrenal venous sampling was 65.2% (15/23). The lateralization results of 68Ga-pentixafor PET/CT supported the clinical decisions of 20 patients with PA, 90% of whom showed effectiveness in treatment. The SUVmax on the dominant side of the surgically treated patients was higher than that of patients treated with drugs. The SUVmax of the KCNJ5 mutant group was higher than that of the KCNJ5 wild group, and 68Ga-Pentixafor uptake was correlated with KCNJ5 gene status.Conclusions: 68Ga-Pentixafor PET/CT proves beneficial for patients with PA with bilateral lesions on CT. The treatment is generally effective based on the results of PET lateralization. Simultaneously, a certain relationship exists between 68Ga-Pentixafor PET/CT and KCNJ5 gene status, warranting further analysis.","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"61"},"PeriodicalIF":3.1000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11224210/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-024-01125-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Subtype diagnosis of primary aldosteronism (PA) is used to determine treatment, and the potential utility of ⁶⁸Ga-pentixafor PET/CT for investigation of PA has long been recognized. The study aimed to evaluate the clinical value of ⁶⁸Ga-pentixafor PET/CT in the diagnosis and prognosis of patients with bilateral lesions identified by CT.

Methods: In total, 25 patients with PA and bilateral lesions on CT were retrospectively evaluated. All patients underwent ⁶⁸Ga-Pentixafor PET/CT and adrenal vein sampling. The analysis focused on establishing the relationship between bilateral adrenal lesions SUVmax and the ratio of bilateral adrenal lesions SUVmax (CON) and clinical diagnosis, treatment outcomes, and KCNJ5 gene status.

Results: The concordance rate between ⁶⁸Ga-Pentixafor PET/CT and adrenal venous sampling was 65.2% (15/23). The lateralization results of ⁶⁸Ga-pentixafor PET/CT supported the clinical decisions of 20 patients with PA, 90% of whom showed effectiveness in treatment. The SUVmax on the dominant side of the surgically treated patients was higher than that of patients treated with drugs. The SUVmax of the KCNJ5 mutant group was higher than that of the KCNJ5 wild group, and ⁶⁸Ga-Pentixafor uptake was correlated with KCNJ5 gene status.

Conclusions: ⁶⁸Ga-Pentixafor PET/CT proves beneficial for patients with PA with bilateral lesions on CT. The treatment is generally effective based on the results of PET lateralization. Simultaneously, a certain relationship exists between ⁶⁸Ga-Pentixafor PET/CT and KCNJ5 gene status, warranting further analysis.

查看原文本刊更多论文

68Ga-pentixafor PET/CT 在原发性醛固酮增多症和双侧病变患者中的临床价值：一项单中心研究的初步结果。

背景：原发性醛固酮增多症（PA）的亚型诊断用于确定治疗方法，而68Ga-pentixafor PET/CT在PA检查中的潜在作用早已得到认可。该研究旨在评估 68Ga-pentixafor PET/CT 在 CT 发现双侧病变患者的诊断和预后中的临床价值：方法：共对 25 例 CT 显示双侧病变的 PA 患者进行了回顾性评估。所有患者均接受了 68Ga-Pentixafor PET/CT 和肾上腺静脉取样。分析的重点是确定双侧肾上腺病变 SUVmax 和双侧肾上腺病变 SUVmax 比值（CON）与临床诊断、治疗结果和 KCNJ5 基因状态之间的关系：68Ga-Pentixafor PET/CT 与肾上腺静脉取样的吻合率为 65.2%（15/23）。68Ga-pentixafor PET/CT 的侧位结果支持 20 例 PA 患者的临床决策，其中 90% 的患者显示治疗有效。手术治疗患者优势侧的 SUVmax 高于药物治疗患者。KCNJ5突变组的SUVmax高于KCNJ5野生组，68Ga-Pentixafor摄取与KCNJ5基因状态相关：68Ga-Pentixafor正电子发射计算机断层扫描（PET/CT）对CT显示双侧病变的PA患者有益。结论：68Ga-Pentixafor PET/CT 对 CT 显示双侧病变的 PA 患者有益。同时，68Ga-Pentixafor PET/CT 与 KCNJ5 基因状态之间存在一定的关系，值得进一步分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-

CiteScore

5.90

自引率

3.10%

发文量

审稿时长

13 weeks

期刊介绍： EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.